Psylink Secures €501,521 In Pre-seed Round

The company focuses on developing innovative treatments for mental health disorders, especially for patients who don’t respond to conventional antidepressants—a group that makes up around 30–40% of cases.

Psylink’s approach combines two pillars: a sustainable biotech process that uses engineered yeast cells to produce natural compounds in an eco-friendly, scalable way; and a research focus on discovering new therapies for conditions like depression and PTSD by studying psilocybin and similar fungal metabolites at the molecular level.

Laura Korsakova, CEO of Psylink, shared: At Psylink we’re developing science-based therapies inspired by nature to help those who haven’t benefited from conventional treatments. We're proud to partner with investors who recognize the urgency and potential of this work. Our multidisciplinary team is united by a clear mission: to create safe, effective and sustainable solutions for mental health, drawing on the rich diversity of bioactive compounds found in plants and fungi.

Psylink, working at the crossroads of biotechnology, neuroscience, and natural product discovery, is well-placed to drive the next wave of mental health treatments. The €501K pre-seed round was led by Coinvest Capital, with participation from a group of angel investors, as well as Firstpick and BSV Ventures.

Read Also - LIfT BioSciences Secures Record €12M Grant To Launch Human Cancer Trials

Viktorija Trimbel, Managing Director of Coinvest Capital, noted: Psylink stands out by combining rigorous biotechnology with the therapeutic potential of natural compounds an approach that is not only innovative but also grounded in strong scientific validation. What impressed us is their ability to bridge traditional wisdom and modern neuroscience. This is exactly the kind of transformative innovation the mental healthcare market urgently needs, and we believe Psylink is well-positioned to lead in this emerging space.

Erin Gainer, who leads the angel investor syndicate, highlighted that Psylink’s work on next generation psychedelic derivatives has the potential to greatly expand treatment options for people struggling with mental health conditions. She added:

I’m honoured to support the team at this early stage and to help bring these much-needed therapies closer to those who need them most.

Sandra Golbreich, Partner at BSV Ventures, described Psylink as a standout deep-tech innovator from the region—addressing a global challenge with solid scientific grounding and a clear mission.

We’re proud to support a team developing real biotech with the potential to transform how we treat mental health.

The funding will support the development of Psylink’s proprietary biotech platform for sustainably producing plant- and fungi-based compounds. It will also enable the screening and testing of new molecular candidates, speeding up the discovery and preclinical validation of promising treatments.

About Psylink

Founded in 2020, Psylink developing a new class of targeted psychedelic agents that precisely interact with serotonin receptors. Using synthetic biology and genome engineering, they create known and novel psychedelic derivatives for preclinical and clinical research aimed at treating the most debilitating mental health disorders.